Stemline Therapeutics, Inc. (NASDAQ: STML) today announced the pricing of an underwritten public offering of 3,700,000 shares of its common ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE